Here's Why AbbVie Inc. Fell 18.3% in March

MarketsMotley Fool

What happened

Shares of AbbVie Inc. (NYSE: ABBV), a big U.S. pharma, dropped 18.3% in March, according to data from S&P Global Market Intelligence. A high-profile lung cancer candidate missed the mark during an important trial.

Continue Reading Below

So what

Rova-T was the early clinical-stage asset that inspired AbbVie to pay a stunning $5.8 billion for Stemcentryx just two years ago. To justify the splurge, AbbVie pointed to a 44% response rate among a group of advanced stage small cell lung cancer patients with tumors that express Rova-T's target. AbbVie also pointed to a chance to apply for accelerated approval and become the first available treatment for these patients after they failed two previous courses of therapy.

The market shaved around $23 billion from AbbVie's market cap on the day the company announced it wouldn't be seeking an accelerated approval for Rova-T in the third-line setting. AbbVie's expensive experimental drug helped shrink tumors for just 16% of patients during the mid-stage Trinity study.

Now what

It might not be game over for Rova-T but it seems unlikely that AbbVie will realize a positive return on its investment. That said, it looks like the market-beating has gone a bit too far. The company's market cap has fallen around $36 billion since the announcement.

Seeing ordinary results from a $5.8 billion gamble is enough to shake anyone's confidence, but don't let the Rova-T upset convince you that the rest of AbbVie's pipeline is on shaky ground. In fact, there are at least three late-stage candidates with blockbuster potential getting close to the finish line.

10 stocks we like better than AbbVieWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 2, 2018

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.